1. Genome-Wide Profiling of Prognostic Alternative Splicing Signature in Colorectal Cancer
   Zhen Zong et al, 2018, Frontiers in Oncology CrossRef
2. Identification of Differentially Expressed Splice Variants by the Proteogenomic Pipeline Splicify
   Malgorzata A. Komor et al, 2017, Molecular & Cellular Proteomics CrossRef
3. Targeted splicing therapy: new strategies for colorectal cancer
   Yifeng Zheng et al, 2023, Frontiers in Oncology CrossRef
4. The effect of spleen tyrosine kinase inhibitor R406 on diabetic retinopathy in experimental diabetic rats
   Xian Su et al, 2020, International Ophthalmology CrossRef
5. Melittin inhibited glycolysis and induced cell apoptosis in cisplatinresistant lung adenocarcinoma cells via TRIM8
   SUFANG ZHANG et al, 2021, BIOCELL CrossRef
6. Biochemical characterization of spleen tyrosine kinase (SYK) isoforms in platelets
   Pankaj Kumar Singh et al, 2023, Platelets CrossRef
7. Knockdown of TRIM65 inhibits autophagy and cisplatin resistance in A549/DDP cells by regulating miR-138-5p/ATG7
   Xufeng Pan et al, 2019, Cell Death & Disease CrossRef
8. High mRNA expression of splice variant SYK short correlates with hepatic disease progression in chemonaive lymph node negative colon cancer patients
   Robert R. J. Coebergh van den Braak et al, 2017, PLOS ONE CrossRef
9. Spleen tyrosine kinase facilitates the progression of papillary thyroid cancer regulated by the hsa_circ_0006417/miR‐377‐3p axis
   Guangmou Tan et al, 2024, Environmental Toxicology CrossRef
10. Targeting the splicing isoforms of spleen tyrosine kinase affects the viability of colorectal cancer cells
    Vincent Denis et al, 2022, PLOS ONE CrossRef
11. Alternative RNA Splicing—The Trojan Horse of Cancer Cells in Chemotherapy
    Nikolay Mehterov et al, 2021, Genes CrossRef
12. MicroRNA and Alternative mRNA Splicing Events in Cancer Drug Response/Resistance: Potent Therapeutic Targets
    Rahaba Marima et al, 2021, Biomedicines CrossRef